The tweet was deleted by the author.
But we saved everything 🙂.
Outlook Therapeutics has announced plans for a proposed public offering. The move signals the companys intention to raise additional capital from investors.
The offering, if completed, would support funding for future operations and development initiatives. Investors are watching for more details on the size and terms of the offering amid ongoing interest in the biopharmaceutical sector.
Outlook Therapeutics recently issued an update after a meeting with the FDA on its ONS-5010 program, outlining next steps for advancing its treatment for retinal disease. The company continues to pursue regulatory progress on this asset, according to details in a previous update. Investors are monitoring both clinical and financial developments closely.